Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer - A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)

Investigational New Drugs

Volumn 13, Issue 4, 1995, Pages 343-345

  Latreille, Jean ^a   Cormier, Yvon ^b   Martins, Heidi ^c   Goss, Glenwood ^d   Fisher, Bryn ^e   Eisenhauer, Elizabeth A ^e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e Queen's Cancer Research Institute   (Canada)

Author keywords

docetaxel; phase II study; small cell lung cancer

Indexed keywords

DOCETAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; DRUG TOXICITY; EDEMA; FEMALE; FEVER; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SMALL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0029608619     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/BF00873142     Document Type: Article

References (4)

1. TM): Not simply two of a kind
2. On behalf of the Early Clinical Trials Group of the EORTC. Activity of Docetaxel (Taxotere) in Small Cell Lung Cancer
3. Phase II study of Taxol in patients with extensive-stage small cell lung cancer: An Eastern Cooperative Oncology Group Study
4. A phase II trial of taxol and GCSF in previously untreated patients with extensivestage small cell lung cancer